Title: Effects of ibesartan plus perindopril on patients with chronic congestive heart failure
Abstract: Objective To evaluate the safety and efficacy of ibesartan plus perindopril in patients with congestive heart failure(CHF). Methods Ninety six patients with CHF were randomized to treatment group(n= 48) which received perindopril 2~8mg/d plus ibesartan 37.5~150mg/d or control group(n=48) which received perindopril 2~8mg/d besides conventional treatment. After twenty four weeks therapy,functional class,echocardiographic variables,blood potassium,urea nitrogen and creatinine were compared between two groups. Results After twenty four weeks therapy,6-min walk-test,left atrial diameter,end-diastolic volume(EDV) of the left ventricle(LV),end-systolic volume(ESV)of LV,left ventricular ejection fraction(LVEF),fraction shortening(FS),cardiac output(CO) and cardiac index(CI) and heart function improved significantly in two groups(control group: t=2.55,2.04,2.98,3.39,2.58,3.24,3.07,3.28; treatment group: t=2.35,2.14,3.08,3.29,2.56,3.22,3.05,3.18,P0.05). However,treatment group had a more significant improvement in 6-min walk-test,LVEDV,LVESV,LVEF and FS than that of controls (t=2.88,2.20,3.04,2.75,3.19,P0.05). The cardiac function of treatment group improved significantly compared with the controls (χ2=4.85,P 0.05). The differences of blood potassium,urea nitrogen and creatinine before and after treatment in the two groups were not significant(control group: t=3.41,4.22,3.86; treatment group: t=3.46,4.38,3.89,P0.05). Conclusions The study suggests that perindopril plus ibesartan in the treatment of CHF is safe,and more effective than perindopril alone.
Publication Year: 2008
Publication Date: 2008-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot